001     834120
005     20210129230544.0
024 7 _ |a 10.1093/neuonc/nox112
|2 doi
024 7 _ |a 1522-8517
|2 ISSN
024 7 _ |a 1523-5866
|2 ISSN
024 7 _ |a pmid:28605532
|2 pmid
024 7 _ |a WOS:000417204200010
|2 WOS
024 7 _ |a altmetric:29918857
|2 altmetric
037 _ _ |a FZJ-2017-04120
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Galldiks, Norbert
|0 P:(DE-Juel1)143792
|b 0
|e Corresponding author
|u fzj
245 _ _ |a PET Imaging in Patients with Meningioma - Report of the RANO/PET Group
260 _ _ |a Oxford
|c 2017
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1512117526_28138
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Meningiomas are the most frequent nonglial primary brain tumors and represent about 30% of brain tumors. Usually, diagnosis and treatment planning are based on neuroimaging using mainly MRI or, rarely, CT. Most common treatment options are neurosurgical resection and radiotherapy (eg, radiosurgery, external fractionated radiotherapy). For follow-up after treatment, a structural imaging technique such as MRI or CT is used. However, these structural imaging modalities have limitations, particularly in terms of tumor delineation as well as diagnosis of posttherapeutic reactive changes. Molecular imaging techniques such as PET can characterize specific metabolic and cellular features which may provide clinically relevant information beyond that obtained from structural MR or CT imaging alone. Currently, the use of PET in meningioma patients is steadily increasing. In the present article, we provide recommendations for the use of PET imaging in the clinical management of meningiomas based on evidence generated from studies being validated by histology or clinical course.
536 _ _ |a 573 - Neuroimaging (POF3-573)
|0 G:(DE-HGF)POF3-573
|c POF3-573
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Albert, Nathalie L.
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Sommerauer, Michael
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Grosu, Anca L.
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Ganswindt, Ute
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Law, Ian
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Preusser, Matthias
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Le Rhun, Emilie
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Vogelbaum, Michael A.
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Zadeh, Gelareh
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Dhermain, Fr?d?ric
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Weller, Michael
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Langen, Karl-Josef
|0 P:(DE-Juel1)131777
|b 12
|u fzj
700 1 _ |a Tonn, J?rg C.
|0 P:(DE-HGF)0
|b 13
773 _ _ |a 10.1093/neuonc/nox112
|0 PERI:(DE-600)2094060-9
|n 12
|p 1576–1587
|t Neuro-Oncology
|v 19
|y 2017
|x 1523-5866
856 4 _ |u https://juser.fz-juelich.de/record/834120/files/nox112.pdf
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/834120/files/nox112.gif?subformat=icon
|x icon
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/834120/files/nox112.jpg?subformat=icon-1440
|x icon-1440
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/834120/files/nox112.jpg?subformat=icon-180
|x icon-180
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/834120/files/nox112.jpg?subformat=icon-640
|x icon-640
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/834120/files/nox112.pdf?subformat=pdfa
|x pdfa
|y Restricted
909 C O |o oai:juser.fz-juelich.de:834120
|p VDB
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)143792
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 12
|6 P:(DE-Juel1)131777
913 1 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-573
|2 G:(DE-HGF)POF3-500
|v Neuroimaging
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2017
915 _ _ |a Allianz-Lizenz / DFG
|0 StatID:(DE-HGF)0400
|2 StatID
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEURO-ONCOLOGY : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEURO-ONCOLOGY : 2015
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
920 1 _ |0 I:(DE-Juel1)INM-4-20090406
|k INM-4
|l Physik der Medizinischen Bildgebung
|x 1
920 1 _ |0 I:(DE-82)080010_20140620
|k JARA-BRAIN
|l JARA-BRAIN
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 _ _ |a I:(DE-Juel1)INM-4-20090406
980 _ _ |a I:(DE-82)080010_20140620
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21